Valneva today announced that the Brazilian Health Regulatory Agency (ANVISA) has authorized its live attenuated single-dose chikungunya vaccine (Ixchiq) for use in people ages 18 and older, marking the first approval of a chikungunya vaccine in an endemic country.
.jpg)
Brazil has been the hardest hit country in the Americas, recording more than 1 million cases between January 2019 and July 2024. In its announcement, the company said the approval paves the way for large-scale clinical trials in Brazil, including phase 4 trials to generate more data on vaccine effectiveness in the wake of approvals in the United States and Europe.
Headway against a debilitating disease
The Coalition for Epidemic Preparedness Innovations (CEPI) is supporting those trials. Valneva said ANVISA continues to evaluate a chikungunya vaccine candidate that, if approved, will be made and distributed by Instituto Butantan in collaboration with Valneva.
Richard Hatchett, MD, CEPI’s chief executive officer, said Brazil’s approval is a significant step to expand the vaccine’s use for travelers as well as populations in chikungunya-affected countries. “ANVISA’s marketing authorization of the vaccine offers new hope in the fight against the debilitating disease and allows us to make headway in our goal to protect the tens of thousands in the country who suffer from chikungunya each year,” he said.